肿瘤射频消融治疗后的免疫反应及抗肿瘤效应

doi:10.3760/cma.j.issn.1673-422X.2013.11.008

摘要/Abstract

摘要： 射频消融治疗不仅造成局部肿瘤细胞的坏死，产生免疫原性的肿瘤相关抗原，还可产生大量炎性细胞因子和多种免疫原性介质，促进免疫细胞的局部浸润和活化，刺激免疫系统产生一定的抗肿瘤效应，但是这种抗肿瘤作用的强度较弱，不足以抵抗肿瘤生长。将射频消融治疗联合特定的免疫治疗如免疫刺激剂、过继免疫细胞治疗、树突状细胞疫苗、单克隆抗体等，可以取得最大临床获益，是免疫治疗有机融入肿瘤综合治疗的一个很好的模式。

关键词: 肿瘤, 免疫系统, 细胞因子类, 淋巴细胞, 射频消融

Abstract: Radiofrequency ablation therapy not only causes the necrosis of localized tumor cells, but also produces immunogenic tumor associated antigens and a large number of inflammatory cytokines and a variety of immunogenic mediums, which promotes the local infiltration and activation of immune cells and stimulates the immune system to produce certain antitumor effect. But the intensity of antitumor effect is feeble and is insufficient to inhibit the growth of tumor cells. Radiofrequency ablation therapy combined with special immunotherapies, such as immune stimulants, adoptive immunity cells therapy, dendritic cell vaccines, monoclonal antibodies and so on, can maximize the clinical benefit, which is a good pattern about tumor comprehensive treatment containing immunotherapy.

Key words: Neoplasms, Immune system, Cytokines, Lymphocytes, Radiofrequency ablation

蔡凯, 张闯, 江涛. 肿瘤射频消融治疗后的免疫反应及抗肿瘤效应[J]. 国际肿瘤学杂志, 2013, 40(11): 826-829.

CAI Kai, ZHANG Chuang, JIANG Tao. Immune responses and antitumor effects after radiofrequency ablation therapy in tumor patients[J]. Journal of International Oncology, 2013, 40(11): 826-829.

参考文献

［1］中国抗癌协会肝癌专业委员会，中国抗癌协会临床肿瘤学协作专业委员会，中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识. 肿瘤, 2011, 31(5): 385-388. ［2］ Waitz R, Solomon SB. Can local radiofrequency ablation of tumors generate systemic immunity against metastatic disease? Radiology, 2009, 251(1): 1-2. ［3］ Haen SP, Pereira PL, Salih HR, et al. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol, 2011, 2011:160250. ［4］ Goldberg SN. Science to practice: can we expand focal interventional oncologic ablation treatments into an effective systemic therapy?. Radiology, 2013,267(2):321-323. ［5］ Gravante G, Ong SL, Metcalfe MS, et al. The effects of radiofrequency ablation on the hepatic parenchyma: histological bases for tumor recurrences. Surg Oncol, 2011,20(4):237-245. ［6］ Gravante G, Sconocchia G, Ong SL, et al. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int, 2009,29(1):18-24. ［7］ Fietta AM, Morosini M, Passadore I, et al. Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol, 2009, 70(7):477-486. ［8］ Haen SP, Gouttefangeas C, Schmidt D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones, 2011,16(5):495-504. ［9］ Zerbini A, Pilli M, Fagnoni F, et al. Increased immunostimulatory activity conferred to antigenpresenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother, 2008, 31(3):271-282. ［10］ Dromi SA, Walsh MP, Herby S, et al. Radiofrequency ablation induces antigenpresenting cell infiltration and amplification of weak tumorinduced immunity. Radiology, 2009,251(1):58-66. ［11］ Wissniowski TT, Hansler J, Neureiter D, et al. Activation of tumorspecific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res, 2003,63(19):6496-6500. ［12］ Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radiofrequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol, 2006,12(23): 3716-3721. ［13］ Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol, 2005, 43(5):817-822. ［14］ Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor specific T-cell responses. Cancer Res, 2006, 66(2):1139-1146. ［15］ Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol, 2012, 40(1):63-70. ［16］ Napoletano C, Taurino F, Biffoni M, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2):481-490. ［17］崇杨，江涛，张东华，等. 射频消融术对原发性肝癌患者甲胎蛋白和外周血CD4+CD25+Foxp3+Treg细胞的影响. 江苏大学学报（医学版）, 2013,23(2): 177-179. ［18］ Liu Q, Zhai B, Yang W, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther, 2009, 17(12):2049-2057. ［19］ Johnson EE, Yamane BH, Buhtoiarov IN, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res, 2009, 15(15):4875-4884. ［20］ SanchezOrtiz RF, Tannir N, Ahrar K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol, 2003, 170(1): 178-179. ［21］ Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther, 2010, 9(11):903-907. ［22］ Kroeze SG, Daenen LG, Nijkamp MW, et al. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model. J Urol, 2012, 188(2):607-614. ［23］ Fagnoni FF, Zerbini A, Pelosi G, et al. Combination of radiofrequency ablation and immunotherapy. Front Biosci, 2008, 13:369-381.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.